Now Recruiting: Sarcoma Clinical Trials

As a National Cancer Institute-designated comprehensive cancer center, City of Hope's sarcoma cancer program is a nationally recognized leader in the research and treatment of sarcomas. As a cancer center whose primary focus is cancer treatment and care, City of Hope has been named one of America's top cancer hospitals by U.S. News & World Report for over a decade, with our physicians consistently being named among "America's Top Doctors" by Castle Connolly.
 
To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials.
 

Soft Tissue Sarcoma

NCT04339738: Principal investigator Mark Agulnik, M.D., is actively recruiting patients for a Phase 2 clinical trial studying the benefits of the addition of nivolumab to chemotherapy in patients with soft tissue sarcoma.
 
Clinical Trials Icon

Patient Enrollment Qualifications

  • 18 years of age or older
  • Histologically confirmed cutaneous or visceral angiosarcoma, where curative treatment is either not possible or curative modality therapy is declined
  • Eastern Cooperative Oncology Group performance status 0-1
 

Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

NCT04200443: Principal investigator Mark Agulnik, M.D.  is now enrolling patients facing unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas for a study on the benefits of cabozantinib and temozolomide during treatment. 
 
Clinical Trials Icon
  • 18 years of age or older 
  • A confirmed diagnosis of unresectable or metastatic: Uterine and nonuterine leiomyosarcoma or Other soft tissue sarcoma (nonleiomyosarcoma) 
  • An Eastern Cooperative Oncology Group performance status of 0-1
 
 

Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT04044768: Principal investigator is now enrolling patients in a Phase 1 study on the efficacy and safety of ADP-A2M4 in HLA-A *02 eligible and MAGE-A4 positive patients with metastatic or inoperable synovial sarcoma or myxoid round cell liposarcoma (MRCLS). 
 
Clinical Trials Icon
  • Age 16 to 75 years of age 
  • Confirmed diagnosis of advanced synovial sarcoma or myxoid liposarcoma/MRCLS.
  • Measurable disease according to RECIST v1.1
 
 

Advanced Sarcoma Harboring Alterations 

NCT04595747: Principal investigator is actively recruiting patients for a Phase 2 study on the benefits of rogaratinib in treating patients with sarcoma that has a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor (GIST). 
 
Clinical Trials Icon

Patient Enrollment Qualifications

  • 18 years of age or older
  • Confirmed sarcoma with FGFR alteration identified by next-generation sequencing profiling, with the exception of SDH-deficient GIST who can be enrolled regardless of FGFR status
  • Eastern Cooperative Oncology Group performance status of ≤ 2